(Yicai Global) Nov. 1 -- Leading gene technology research and development group BGI Genomics Co. [SHE:300676] signed an agreement with Guangdong-based traditional Chinese medicine (TCM) firm Kangmei Pharmaceutical Co. [SHA:600518] in Shenzhen yesterday. They will promote the application of gene research in the TCM industry.
The companies said in sperate announcements that they plan to establish research institutes and joint ventures for long-term cooperation in platform construction, basic research and personnel training.
BGI Genomics is committed to the application of cutting-edge gene research results in promoting health and wellness. It said that during this cooperation, it will combine the strength of Kangmei Pharmaceutical's TCM industry chain to promote the innovative application of genetic technology in the field of TCM.
Kangmei Pharmaceutical said that the tie-up is conducive to strengthening its research capacity in the development of TCM products, the gene detection of medical materials, and the evaluation of the efficacy of TCM, and will contribute to its long-term advancement.
Founded in 1999, BGI Genomics was initially a research institute in Beijing. It published several papers in international authoritative journals such as Nature and Science, and acquired a leading American gene sequencing enterprise -- Complete Genomics Inc. -- in 2013.